← Leaderboards
Ming-Fen Ho
Mayo Clinic Rochester
$2,322,565
Attributed
$2,743,541
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $962.5K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,743,541 · 3
By mechanism
R01$2,094,791 · 2
K01$648,750 · 1
Top collaborators
- Richard M Weinshilboum2 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Victor M. Karpyak$3,624,336
- Joanna M Biernacka$6,043,821
- Patricia Devaux$2,961,490
- Nathan P Staff$5,882,116
- Doo-Sup Choi$10,860,820
Others in their field
Other Emerging Leaders on “Molecular”
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Lynn Briscoe · Leidos Biomedical Research, Inc.$137,360,557
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$109,548,439
- Leonard Freedmand · Leidos Biomedical Research, Inc.$85,594,314
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$76,895,673
- Scott Hensley · University Of Pennsylvania$41,662,743
Research focus
MolecularGenomicsTherapeutic AgentsMultiple OmicsPharmacotherapyResponseFunctional DisorderPathway InteractionsGenesInduced Pluripotent Stem CellPharmaceutical PreparationsPharmacogenomicsInsightInnovationCell TypeCellsInduced Pluripotent Stem Cell TechnologyNeurogliaFunctional GenomicsMolecular ProfilingBiological ModelsNeuronsDesignMolecular Probes
Grant awards (10)
Alcohol Use Disorder: Acamprosate Pharmacometabolomics-informed Pharmacogenomics$426,787
R01 · FY2025 · AA
Single cell multi-omics of iPSC-derived brain organoids from patients with opioid use disorder: synthetic opioids as molecular probes$417,613
R01 · FY2025 · DA · contact PI
Single cell multi-omics of iPSC-derived brain organoids from patients with opioid use disorder: synthetic opioids as molecular probes$417,613
R01 · FY2024 · DA · contact PI
Alcohol Use Disorder: Acamprosate Pharmacometabolomics-informed Pharmacogenomics$415,165
R01 · FY2024 · AA
Acamprosate pharmacogenomics: iPSC based model of alcohol use disorder$129,750
K01 · FY2024 · AA · contact PI
Single cell multi-omics of iPSC-derived brain organoids from patients with opioid use disorder: synthetic opioids as molecular probes$417,613
R01 · FY2023 · DA · contact PI
Acamprosate pharmacogenomics: iPSC based model of alcohol use disorder$129,750
K01 · FY2023 · AA · contact PI
Acamprosate pharmacogenomics: iPSC based model of alcohol use disorder$129,750
K01 · FY2022 · AA · contact PI
Acamprosate pharmacogenomics: iPSC based model of alcohol use disorder$129,750
K01 · FY2021 · AA · contact PI
Acamprosate pharmacogenomics: iPSC based model of alcohol use disorder$129,750
K01 · FY2019 · AA · contact PI